Therapeutic effect of pioglitazone on chronic kidney disease (CKD).

Therapeutic effect of pioglitazone on chronic kidney disease (CKD). - Treatment of CKD by pioglitazone.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001017

Enrollment

Registered

2008-02-27

Start date

2008-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease (CKD)

Interventions

Patients of intervention group are treated with pioglitazone orally from the dose of 15mg/day, increased up to 30-45mg/day within one month, and continued for 6 month. The efficacy and side effects ar

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non-diabetic chronic kidney disease with proteinuria of 0.3g/day (1+ by test tape) or more.

Exclusion criteria

Exclusion criteria: 1. Chronic renal failure with serum creatinine level above 3.0 mg/dl. 2. Severe liver dysfunction. 3. Severe edema or chronic heart failure. 4. Past history of allergy against pioglitazone. 5. Pregnant or breast feeding patients. 6. Patients with ongoing steroid therapy.

Design outcomes

Primary

Measure	Time frame
Decrease in levels of proteinuria	—

Secondary

Measure	Time frame
Inhibition of deterioration in renal function (serum creatinine, estimated-GFR)	—

Countries

Japan

Contacts

Public ContactTakashi Oda

National Defense Medical College Department of Nephrology

takashio@ndmc.ac.jp04-2995-1609

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026